Literature DB >> 19551519

A two one-sided parametric tolerance interval test for control of delivered dose uniformity--part 2--effect of changing parameters.

Steve Novick1, David Christopher, Monisha Dey, Svetlana Lyapustina, Michael Golden, Stefan Leiner, Bruce Wyka, Hans-Joachim Delzeit, Chris Novak, Gregory Larner.   

Abstract

This article examines the effects of changing parameters in the test which was proposed by the FDA at the October 2005 Advisory Committee meeting for confirming delivered dose uniformity in orally inhaled and nasal drug products. This article is an extension of the characterization study presented in an accompanying article (Part 1). The goal of this study is to understand how parameters of the test affect the test performance. The effects of changing test parameters such as target interval, maximum allowable proportion in the tail area, and sample size are examined. The results show that changing the maximum allowable tail area and/or the target interval have the largest impact on the test outcomes, i.e., probability of acceptance for a given batch mean and standard deviation. The presented information may provide potential users of the test with a set of tools for optimizing the test characteristics for a particular product.

Mesh:

Substances:

Year:  2009        PMID: 19551519      PMCID: PMC2802172          DOI: 10.1208/s12249-009-9269-3

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  1 in total

1.  Challenges and opportunities in implementing the FDA default parametric tolerance interval two one-sided test for delivered dose uniformity of orally inhaled products.

Authors:  Greg Larner; Andrew Cooper; Svetlana Lyapustina; Stefan Leiner; David Christopher; Helen Strickland; Michael Golden; Hans-Joachim Delzeit; Emil M Friedman
Journal:  AAPS PharmSciTech       Date:  2011-09-08       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.